Prasad’s Departure Could Be ‘Big Win’ For Biotech—Especially Rare Disease Space: Stifel
Some biotechs that had seen regulatory setbacks under Center for Biologics Evaluation and Research director Vinay Prasad experienced stock bumps Monday morning. Under Prasad’s leadership, the rare disease space has suffered a series of controversial rejections.
Prasad’s Departure Could Be ‘Big Win’ For Biotech—Especially Rare Disease Space: Stifel Read More »
